MCID: PDT021
MIFTS: 34

Pediatric Osteosarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Pediatric Osteosarcoma

MalaCards integrated aliases for Pediatric Osteosarcoma:

Name: Pediatric Osteosarcoma 12 15
Childhood Osteosarcoma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:3361
NCIt 50 C6585
UMLS 70 C1332986

Summaries for Pediatric Osteosarcoma

MalaCards based summary : Pediatric Osteosarcoma, also known as childhood osteosarcoma, is related to osteogenic sarcoma and bone resorption disease. An important gene associated with Pediatric Osteosarcoma is SLC19A1 (Solute Carrier Family 19 Member 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Glucose / Energy Metabolism. The drugs Methotrexate and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include bone, pituitary and kidney, and related phenotype is integument.

Related Diseases for Pediatric Osteosarcoma

Diseases related to Pediatric Osteosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Related Disease Score Top Affiliating Genes
1 osteogenic sarcoma 30.2 SOX4 SLC19A1 RECQL4 IGF1 DHFR
2 bone resorption disease 29.5 MIR214 MIR188 IGF1
3 sudden sensorineural hearing loss 10.3 MTR MTHFR
4 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 10.3 MTR MTHFR
5 intracranial vasospasm 10.3 MTR MTHFR
6 adult acute lymphocytic leukemia 10.2 SHMT1 MTR MTHFR
7 myelomeningocele 10.2 SLC19A1 MTR MTHFR
8 homocysteinemia 10.2 SLC19A1 MTR MTHFR
9 choline deficiency disease 10.2 MTR MTHFR
10 cutis laxa, autosomal dominant 3 10.2 MTR MTHFR DHFR
11 cutis laxa, autosomal dominant 2 10.2 MTR MTHFR DHFR
12 folate malabsorption, hereditary 10.1 SLC19A1 MTR DHFR
13 anencephaly 10.1 MTR MTHFR DHFR
14 bone cancer 10.1
15 slipped capital femoral epiphysis 10.1 IGFBP3 IGF1
16 secondary adrenal insufficiency 10.0 IGFBP3 IGF1
17 methotrexate toxicity 10.0 SLC19A1 MTR MTHFR DHFR
18 childhood leukemia 10.0 SLC19A1 MTR MTHFR DHFR
19 megaloblastic anemia 10.0 SLC19A1 MTR MTHFR DHFR
20 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.0 IGFBP3 IGF1
21 mucositis 10.0
22 sarcoma 10.0
23 neutropenia 10.0
24 spindle cell sarcoma 10.0
25 colorectal adenoma 10.0 MTR MTHFR IGF1
26 mammographic density 10.0 IGFBP3 IGF1
27 potter's syndrome 10.0 IGFBP3 IGF1
28 marasmus 10.0 IGFBP3 IGF1
29 central precocious puberty 10.0 IGFBP3 IGF1
30 bone disease 9.9
31 localized osteosarcoma 9.9
32 fetal macrosomia 9.9 IGFBP3 IGF1
33 nutritional deficiency disease 9.9 MTHFR IGFBP3 IGF1
34 bone remodeling disease 9.9 MIR214 MIR188 IGF1
35 pituitary gland disease 9.9 MIR210 IGFBP3 IGF1
36 osteoporosis, juvenile 9.9 MIR188 IGFBP3 IGF1
37 turner syndrome 9.9 MTHFR IGFBP3 IGF1
38 skin tag 9.9 IGFBP3 IGF1
39 neural tube defects 9.9 SLC19A1 SHMT1 MTR MTHFR DHFR
40 empty sella syndrome 9.8 IGFBP3 IGF1
41 cardiovascular system disease 9.8 MTR MTHFR MIR210 IGF1
42 retinoblastoma 9.8
43 baller-gerold syndrome 9.8
44 rothmund-thomson syndrome, type 2 9.8
45 leukemia, acute myeloid 9.8
46 bone mineral density quantitative trait locus 3 9.8
47 ewing sarcoma 9.8
48 myelodysplastic syndrome 9.8
49 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
50 oral squamous cell carcinoma 9.8

Graphical network of the top 20 diseases related to Pediatric Osteosarcoma:



Diseases related to Pediatric Osteosarcoma

Symptoms & Phenotypes for Pediatric Osteosarcoma

MGI Mouse Phenotypes related to Pediatric Osteosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.23 DHFR IGF1 IGFBP3 MTHFR RECQL4 ROCK1

Drugs & Therapeutics for Pediatric Osteosarcoma

Drugs for Pediatric Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved 1959-05-2, 59-05-2 126941
2
Cisplatin Approved 15663-27-1 84093 441203 2767
3
Sargramostim Approved, Investigational 123774-72-1, 83869-56-1
4
Mesna Approved, Investigational 3375-50-6 598
5
Levoleucovorin Approved, Investigational 68538-85-2 149436
6
Dexrazoxane Approved, Withdrawn 24584-09-6 71384
7
Doxorubicin Approved, Investigational 23214-92-8 31703
8
Ifosfamide Approved 3778-73-2 3690
9
leucovorin Approved 58-05-9 6006
10
Gemcitabine Approved 95058-81-4 60750
11
Carboplatin Approved 41575-94-4 10339178 498142 38904
12
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
13
Molgramostim Investigational 99283-10-0
14
Isophosphamide mustard 100427
15
Liposomal doxorubicin 31703
16 Folic Acid Antagonists
17 Micronutrients
18 Antidotes
19 razoxane
20 Trace Elements
21 Vitamin B9
22 Nutrients
23 Cardiotonic Agents
24 Antirheumatic Agents
25 Immunosuppressive Agents
26 Antimitotic Agents
27 Folate
28 Alkylating Agents
29 Vitamin B Complex
30 Antibiotics, Antitubercular
31 Protective Agents
32 Vitamins
33 Antiviral Agents
34 Anti-Infective Agents
35 Anti-Bacterial Agents
36 Antimetabolites
37 Immunologic Factors
38 Dermatologic Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 The Impact of Cancer and Treatment-related Effects on the Physical and Psychosocial Well-being and Quality of Life Among Hong Kong Chinese Survivors of Childhood Osteosarcoma: An Exploratory Study Recruiting NCT03298971
2 Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity Recruiting NCT03139318
3 Outpatient Chemotherapy in Pediatric Osteosarcoma: Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy Terminated NCT00673179 Doxorubicin;Cisplatin;Methotrexate;Leucovorin;Dexrazoxane;Ifosfamide;Gemcitabine;Sargramostim;Mesna

Search NIH Clinical Center for Pediatric Osteosarcoma

Genetic Tests for Pediatric Osteosarcoma

Anatomical Context for Pediatric Osteosarcoma

MalaCards organs/tissues related to Pediatric Osteosarcoma:

40
Bone, Pituitary, Kidney, Skin, Myeloid, Pineal

Publications for Pediatric Osteosarcoma

Articles related to Pediatric Osteosarcoma:

(show top 50) (show all 193)
# Title Authors PMID Year
1
Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma. 61
33737338 2021
2
Adjuvant sirolimus does not improve outcome in pet dogs receiving standard of care therapy for appendicular osteosarcoma: A prospective, randomized trial of 324 dogs. 61
33753454 2021
3
Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma. 61
33575468 2021
4
Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas. 61
33616477 2021
5
The relation between staging fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography metabolic parameters and tumor necrosis rate in pediatric osteosarcoma patients. 61
33387988 2021
6
Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients. 61
33181717 2020
7
Nanomedicine and drug delivery systems in cancer and regenerative medicine. 61
32351045 2020
8
Cumulative Burden of Chronic Health Conditions in Adult Survivors of Osteosarcoma and Ewing Sarcoma: A Report from the St. Jude Lifetime Cohort Study. 61
32499311 2020
9
Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib. 61
31782150 2020
10
Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma. 61
32674353 2020
11
Comment on: Curative-intent radiotherapy for pediatric osteosarcoma: The St. Jude experience. 61
32293779 2020
12
Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma. 61
32151185 2020
13
Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice. 61
32311470 2020
14
Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. 61
31867853 2020
15
Insights in Osteosarcoma by Proton Nuclear Magnetic Resonance Serum Metabonomics. 61
33178572 2020
16
Outcomes for pediatric patients with osteosarcoma treated with palliative radiotherapy. 61
31407520 2020
17
Joint-preservation surgery for pediatric osteosarcoma of the knee joint. 61
31807972 2019
18
Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. 61
31236944 2019
19
A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine. 61
31546021 2019
20
Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in prediction of response to neoadjuvant chemotherapy in pediatric osteosarcoma. 61
31933554 2019
21
Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcoma. 61
31604778 2019
22
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. 61
30629005 2019
23
Curative-intent radiotherapy for pediatric osteosarcoma: The St. Jude experience. 61
31012273 2019
24
Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon. 61
30946633 2019
25
The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. 61
30651371 2019
26
Lymphocyte-monocyte ratio at day 14 of first cisplatin-doxorubicin chemotherapy is associated with treatment outcome of pediatric patients with localized osteosarcoma. 61
30304898 2019
27
Educational Case: Pediatric Osteosarcoma. 61
30859126 2019
28
Downregulated Adhesion-Associated microRNAs as Prognostic Predictors in Childhood Osteosarcoma. 61
28944406 2019
29
Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. 61
30580500 2019
30
Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma. 61
30704460 2019
31
Immunotherapeutic approaches in pediatric osteosarcoma. 61
28353326 2018
32
Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. 61
30454696 2018
33
Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk. 61
30038050 2018
34
The Effect of Clown Intervention on Self-Report and Biomarker Measures of Stress and Fatigue in Pediatric Osteosarcoma Inpatients: A Pilot Study. 61
29900751 2018
35
The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma. 61
29889801 2018
36
miR‑188 suppresses tumor progression by targeting SOX4 in pediatric osteosarcoma. 61
29749512 2018
37
Growth of epiphysis after epiphyseal-preservation surgery for childhood osteosarcoma around the knee joint. 61
29875014 2018
38
Carbon ion radiotherapy for inoperable pediatric osteosarcoma. 61
29796166 2018
39
Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. 61
29357275 2018
40
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α. 61
29191969 2018
41
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. 61
28806574 2018
42
Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis. 61
29364496 2018
43
Methotrexate Free Chemotherapy and Limb Salvage Surgery for Paediatric Osteosarcoma in India. 61
29416171 2018
44
FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients. 61
28887617 2017
45
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. 61
29390436 2017
46
TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. 61
29163677 2017
47
Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2013. 61
28409896 2017
48
Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina. 61
28937522 2017
49
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma. 61
28267080 2017
50
Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents. 61
27860191 2017

Variations for Pediatric Osteosarcoma

Expression for Pediatric Osteosarcoma

Search GEO for disease gene expression data for Pediatric Osteosarcoma.

Pathways for Pediatric Osteosarcoma

Pathways related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.33 SLC19A1 SHMT1 MTR MTHFR DHFR
2 12.2 SHMT1 MTHFR IGFBP3 HK2
3 12.12 SOX4 ROCK1 MIR30C1 MIR214 MIR210 MIR181C
4
Show member pathways
12 SHMT1 MTR MTHFR HK2
5
Show member pathways
11.99 SLC19A1 SHMT1 MTR MTHFR DHFR
6
Show member pathways
11.51 SHMT1 MTR MTHFR DHFR ATIC
7 10.76 IGFBP3 IGF1
8 10.51 SLC19A1 SHMT1 MTHFR DHFR ATIC

GO Terms for Pediatric Osteosarcoma

Cellular components related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor ternary complex GO:0042567 8.96 IGFBP3 IGF1
2 insulin-like growth factor binding protein complex GO:0016942 8.62 IGFBP3 IGF1

Biological processes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.85 MIR30C1 MIR214 MIR210 MIR188 MIR181C
2 positive regulation of MAPK cascade GO:0043410 9.7 ROCK1 IGFBP3 IGF1
3 positive regulation of cardiac muscle hypertrophy GO:0010613 9.54 ROCK1 IGF1
4 axon regeneration GO:0031103 9.51 MTR DHFR
5 positive regulation of connective tissue replacement GO:1905205 9.49 ROCK1 MIR214
6 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.48 IGFBP3 IGF1
7 methionine biosynthetic process GO:0009086 9.43 MTR MTHFR
8 tetrahydrofolate interconversion GO:0035999 9.4 SHMT1 MTHFR
9 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.37 MIR210 IGF1
10 tetrahydrofolate biosynthetic process GO:0046654 9.32 DHFR ATIC
11 glycine biosynthetic process GO:0006545 9.26 SHMT1 DHFR
12 dihydrofolate metabolic process GO:0046452 9.16 DHFR ATIC
13 tetrahydrofolate metabolic process GO:0046653 9.13 SHMT1 MTHFR DHFR
14 folic acid metabolic process GO:0046655 8.92 SLC19A1 SHMT1 MTHFR DHFR

Molecular functions related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 translation repressor activity, mRNA regulatory element binding GO:0000900 9.16 SHMT1 DHFR
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR30C1 MIR214 MIR210 MIR188 MIR181C
3 folic acid binding GO:0005542 8.96 SLC19A1 DHFR

Sources for Pediatric Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....